# US 2026/0275353 A1 · Compounds to treat inherited retinal disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0275353 A1
- Document ID: US20260275353A1
- Status: Published application
- Kind: A1
- Application number: 19/473,454
- Filed: 2024-04-24
- Published: 2026-09-17
- Earliest claimed: 2023-04-24
- Assignees: Universiteit Gent
- Applicants: Universiteit Gent
- Inventors: Frauke Coppieters; Alfredo Duenas Rey; Manon Bouckaert
- Web page: https://patentgrep.com/patent/US20260275353A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- C12N 9/0006: {acting on CH-OH groups as donors (1.1)}
- C12N 15/67: General methods for enhancing the expression
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N 2320/30: Special therapeutic applications
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/156: Polymorphic or mutational markers
- C12Y 101/013: NADP-retinol dehydrogenase (1.1.1.300)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES

## Abstract

A field of treating inherited retinal disease (IRD). More specifically, the disclosure discloses a target region that is useful to screen for compounds capable of treating inherited retinal disease and discloses specific antisense oligonucleotides (ASOs) useful to treat the latter disease. This disclosure is based on the finding that the variant c.-123C>T in the 5′UTR of the RDH12 gene causes an upstream start codon (uATG) resulting in insufficient RDH12 protein production and hence causes inherited retinal disease. ASOs, which hybridize with a region surrounding or containing the uATG provide steric hindrance for recognition of the upstream start codon, thus redirecting the scanning ribosomes to the primary start codon, which results in increased RDH12 protein production.

## Claims

### Claim at position 1

1-7. (canceled)

### Claim 8

An antisense oligonucleotide (ASO) comprising a polynucleotide that hybridizes under stringent conditions to a region of the RDH12 gene 5′ untranslated region (5′UTR) containing the variant c.-123C>T, wherein the ASO is capable of increasing translation of RDH12 protein.

### Claim 9 (depends on 8)

The ASO of claim 8, wherein the ASO inhibits ribosomal recognition of an upstream start codon (uATG) caused by the variant c.-123C>T.

### Claim 10 (depends on 8)

The ASO of claim 8, wherein the ASO consists of 12 to 25 nucleotides.

### Claim 11 (depends on 8)

The ASO of claim 8, wherein the ASO comprises a polynucleotide selected from SEQ ID NOs: 1-104.

### Claim 12 (depends on 11)

The ASO of claim 11, wherein the ASO comprises a polynucleotide selected from the group consisting of SEQ ID NOs: 2, 35, 36, 38, 39, 40, 41, and 42.

### Claim 13 (depends on 12)

The ASO of claim 12, wherein the ASO increases translation of RDH12 protein in a cell comprising the variant c.-123C>T.

### Claim 14

An antisense oligonucleotide (ASO) comprising means for increasing translation of RDH12 protein in a cell comprising variant c.-123C>T in the 5′UTR of the RDH12 gene,
wherein the means comprises a polynucleotide that hybridizes to the 5′UTR region containing the variant.

### Claim 15 (depends on 14)

The ASO of claim 14, wherein the ASO comprises a polynucleotide selected from SEQ ID NOs: 1-104.

### Claim 16 (depends on 15)

The ASO of claim 15, wherein the ASO comprises a polynucleotide selected from the group consisting of SEQ ID NOs: 2, 35, 36, 38, 39, 40, 41, and 42.

### Claim 17 (depends on 16)

The ASO of claim 16, wherein the ASO increases translation of RDH12 protein in a cell comprising the variant c.-123C>T.

### Claim 18 (depends on 8)

A pharmaceutical composition formulated for intravitreal administration, the pharmaceutical formulation comprising:
the ASO of claim 8 and
a pharmaceutically acceptable carrier.

### Claim 19 (depends on 14)

A pharmaceutical composition formulated for intravitreal administration, the pharmaceutical formulation comprising:
the ASO of claim 14 and
a pharmaceutically acceptable carrier.

### Claim 20 (depends on 18)

The pharmaceutical composition of claim 18, further comprising a stabilizing excipient selected from sugars, polyols, amino acids, and mixtures thereof.

### Claim 21 (depends on 19)

The pharmaceutical composition of claim 19, further comprising a stabilizing excipient selected from sugars, polyols, amino acids, and mixtures thereof.

### Claim 22 (depends on 8)

A method of treating an inherited retinal disease in a subject in need thereof, the method comprising:
administering to the subject the ASO of claim 8.

### Claim 23 (depends on 14)

A method of treating an inherited retinal disease in a subject in need thereof, the method comprising:
administering to the subject the ASO of claim 14.

### Claim 24 (depends on 22)

The method according to claim 22, wherein the ASO comprises a polynucleotide selected from the group consisting of SEQ ID NOs: 2, 35, 36, 38, 39, 40, 41, and 42.

### Claim 25 (depends on 23)

The method according to claim 23, wherein the ASO comprises a polynucleotide selected from the group consisting of SEQ ID NOs: 2, 35, 36, 38, 39, 40, 41, and 42.

### Claim 26 (depends on 23)

The method according to claim 23, wherein the ASO inhibits ribosomal recognition of an upstream start codon (uATG) caused by the variant c.-123C>T.

### Claim 27 (depends on 23)

The method according to claim 23, wherein the ASO increases translation of RDH12 protein in the subject's retinal cells.

### Claim 28 (depends on 8)

A method of increasing translation of RDH12 protein in vitro, the method comprising:
contacting a polynucleotide comprising the variant c.-123C>T in the 5′UTR of the RDH12 gene with the ASO of claim 8.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the ASO comprises a polynucleotide selected from the group consisting of SEQ ID NOs: 2, 35, 36, 38, 39, 40, 41, and 42.

### Claim 30 (depends on 28)

The method according to claim 28, wherein the ASO increases translation of the RDH12 protein by at least 50% compared to a control.

### Claim 31 (depends on 14)

A method of increasing translation of RDH12 protein in vitro, the method comprising:
contacting a polynucleotide comprising the variant c.-123C>T in the 5′UTR of the RDH12 gene with the ASO of claim 14.

### Claim 32

A method of screening a molecule for the ability to increase translation of RDH12 protein, the method comprising:
(a) contacting the molecule with a polynucleotide comprising the variant c.-123C>T in the 5′ untranslated region (5′UTR) of the RDH12 gene; and
(b) detecting an increase in translation of the RDH12 protein.
